Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset
By Robb M. Stewart
Tharimmune's shares were under pressure Thursday despite the company's lead clinical asset receiving what it said was positive feedback from the Food and Drug Administration on a simulation modeling plan.
In premarket trading, the shares were down 6% after climbing sharply earlier in the morning. The stock has climbed almost 60% this year, last closing at $3.22.
Tharimmune said the FDA following a review concurred with its proposed modeling plan for its TH104 nalmefene buccal film opioid treatment, and provided guidance on specific technical elements that the company plans to integrate into the finalized modeling.
It said the FDA's feedback further de-risks the TH104 program.
Tharimmune said it presented its initial pharmacokinetic simulation results and a plan for a more detailed pharmacokinetic modeling for FDA review. The modeling plan represents a critical component in advancing TH104 as a prophylactic countermeasure to mitigate respiratory depression caused by fentanyl and other ultrapotent opioids.
Additionally, the company said it is on track to initiate a comprehensive chemistry, manufacturing, and controls plan, focusing on scaling production and ensuring the quality and consistency of the TH104 buccal film product for advanced clinical development and commercial readiness.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
November 13, 2025 09:38 ET (14:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
What’s Ahead for Stocks This Quarter—and Where to Invest
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
United States